Eleven Biotherapeutics (EBIO) Misses Q3 EPS by 17c

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q3 EPS of ($0.50), $0.17 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $68 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
• Semtech (SMTC) Tops Q2 EPS by 10c, Beats on Revenue; Offers Q3 Guidance
• Semtech surges on strong Q2 beat and upbeat Q3 guidance